title: A prospective double-blind, placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration.
abstract: We aimed to determine the incidence of sensory symptoms (SS) that complicate thalidomide treatment of patients with age-related macular degeneration. In a double-blind prospective study, 38 patients were randomized to receive either thalidomide (100mg twice per day) or placebo for 1year. They were then followed for another year off drug. The SS (numbness, tingling, pins and needles) occurred in nine patients who took thalidomide (9/18; 50%) and in four who took placebo (4/20; 20%). Symptom severity was correlated with the time of onset, but not with cumulative dose. Five patients partially improved when the thalidomide was withdrawn, and three patients developed tremor with the neuropathy. The SS occurred shortly after thalidomide was introduced and we concluded that older patients with macular degeneration should be carefully screened for risk factors of peripheral neuropathy before thalidomide is used in their treatment.
authors.affiliation: Department of Neurology, New Jersey Medical School, 90 Bergen Street, DOC 8100, Newark, New Jersey 07101, USA. souayani@umdnj.edu <souayani@umdnj.edu>
authors.forename: Nizar
authors.initials: N
authors.lastname: Souayah
authors.forename: Sami L
authors.initials: SL
authors.lastname: Khella
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000502:physiology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011446:Prospective Studies; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013792:Thalidomide / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide